회사 개요
GeneDx Holdings Corp. operates as a genomics company that primarily provides genetic testing services, with a core focus on pediatric and rare disease diagnostics utilizing whole exome and genome sequencing technologies. Within the broader Healthcare sector, the firm is specifically categorized under the Diagnostics & Research industry, where it delivers specialized data and information services alongside the development of an AI-based platform for next-generation sequencing. The company demonstrates significant scale with a market capitalization of $1.92B, an annual revenue of $427.54M, and an workforce comprising 1,300 employees. These financial figures position GeneDx as a substantial entity within its niche, indicating a large operational footprint and significant market penetration in the diagnostic testing space relative to peers in the genomics industry.
재무 건전성
GeneDx Holdings Corp. reported revenue of $427.54M and generated EBITDA of $12.65M over the trailing twelve months, yet it recorded a net income of -$21.02M, a discrepancy that reveals a substantial cost structure burdened by non-operating expenses or significant tax implications affecting the bottom line. Despite the reported net loss, the company maintained a free cash flow of $38.06M, which indicates a strong capacity to generate liquidity from operations and provides the financial flexibility to fund capital expenditures or strategic initiatives without relying on external financing. The company's margin profile shows a gross margin of 69.7%, suggesting high efficiency in delivering core testing services, while an operating margin of -10.6% and a profit margin of -4.9% highlight that operating expenses and other costs are currently exceeding operating revenue. In terms of liquidity management, GeneDx holds $171.28M in cash against $113.17M in debt, resulting in a debt-to-equity ratio of 36.72 that characterizes a highly leveraged balance sheet structure. Although the leverage is high, the current ratio of 2.46 suggests that the company possesses ample short-term assets to cover its short-term liabilities, pointing to robust immediate liquidity. Return on Equity stands at -7.6% and Return on Assets at -1.5%, metrics that collectively reveal that management has not yet achieved profitability, resulting in a dilution of shareholder value and a failure to generate positive returns on the capital employed.
밸류에이션 평가
The valuation metrics for GeneDx Holdings Corp. include a forward P/E of 31.88 and a trailing P/E ratio marked as N/A due to the company's current unprofitable status, implying that the market is pricing in significant future earnings growth to justify the current multiple. The price-to-book ratio is 6.22, which indicates that the market is assigning a substantial premium to the company's intangible assets, such as its intellectual property and AI platform, over its tangible book value. Alternative valuation measures include a price-to-sales ratio of 4.49 and an EV/EBITDA of 147.24, figures that suggest investors are willing to pay a high multiple for revenue and earnings power, anticipating a rapid normalization of profitability in the coming years. The stock has exhibited considerable price volatility, trading between a 52-week high of $170.87 and a 52-week low of $55.17, reflecting the speculative nature of the investment in a pre-profitability growth phase. With a beta of 2.19, the stock is significantly more volatile than the broader market, meaning price movements are amplified by approximately 119% relative to general market fluctuations, which increases the risk profile for risk-averse investors.
Growth & Income
GeneDx Holdings Corp. achieved a revenue growth rate of 26.5% year-over-year, while earnings growth is N/A due to the company's recent net losses, implying that top-line expansion is currently occurring without corresponding bottom-line improvement. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, indicating a corporate strategy to reinvest all available earnings and free cash flow back into research, development, and market expansion rather than returning capital to shareholders. This reinvestment approach is typical for companies in the early stages of commercialization within the healthcare diagnostics sector, where capital is required to scale operations and perfect their AI-based sequencing platforms. The overall growth and income profile is defined by aggressive top-line expansion coupled with a complete absence of current income generation, creating a high-risk, high-potential reward scenario dependent on the timely achievement of operational profitability.